Top buyers biopharma, diagnostics, and medtech M&As by upfront cash and equity 2020
In 2020, AstraZeneca paid a total of 39 billion U.S. dollars in upfront cash and equity for merger and acquisition deals, while Gilead paid nearly 28 billion U.S. dollars. This statistic illustrates the top buyers in biopharma therapeutics and platforms, diagnostics, and medtech (also digital health) merger and acquisition deals worldwide in 2020, by upfront cash and equity paid.
